Table 2 Comparison of patients’ baseline clinical characteristics by propensity score matching analysis

Number of patients

21

21

Gender, female (%)

14 (66.7)

14 (66.7)

N.S.

Age, years

72 (74–80)

74 (71–79)

N.S.

ILD, n (%)

N.S.

UIP

3 (14.3)

4 (19.1)

NSIP

18 (85.7)

17 (80.9)

ABT, n (%)

Subcutaneous injection

3 (14.3)

-

Intravenous drip

18 (86.7)

-

JAKi, n (%)

Tofacitinib

-

14 (66.7)

Baricitinib

-

7 (33.3)

Disease duration, years

6 (4–19)

16 (7–26)

N.S.

Stage ≥ III, n (%)

11 (52.3)

12 (57.1)

N.S.

Class ≥ 3, n (%)

3 (14.3)

1 (4.8)

N.S.

ACPA positive, n (%)

18 (85.1)

21 (100)

N.S.

ACPA ≥ 100, n (%)

11 (52,3)

15 (71.4)

N.S.

RF positive, n (%)

18 (85.7)

21 (100)

N.S.

RF ≥ 100, n (%)

14 (66.7)

14 (66.7)

N.S.

DAS28-CRP

4.37 (3.04–5.02)

4.58 (3.50–5.80)

N.S.

mHAQ

0.75 (0.00–1.07)

0.38 (0.07–1.50)

N.S.

Past use of bDMARDs or JAKi, n (%)

9 (42.9)

16 (76.2)

N.S.

Most recent bDMARDs or JAKi, n (%)

N.S.

IL6i

4 (44.4)

7 (43.8)

CTLA4-ig

-

5 (31.3)

TNFi

5 (55.6)

4 (24.0)

JAKi

0 (0.0)

0 (0.0)

Methotrexate, n (%)

10 (47.6)

5 (23.8)

N.S.

Prednisolone, n (%)

17 (81.0)

14 (66.7)

N.S.

Prednisolone dose, mg/day

5.0 (2.3–5.0)

4.8 (0.0–6.0)

N.S.

Smoking, n (%)

N.S.

Never

17 (81.0)

14 (66.7)

Ex-smoker

2 (9.5)

5 (23.8)

Current smoker

2 (9.5)

2 (9.5)

Diabetes mellitus, n (%)

4 (19.1)

2 (9.5)

N.S.